Study blood marker changes in early, symptom-free blood cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Have a known or suspected early (“precursor”) blood condition
- Examples include MGUS, smoldering myeloma, early MDS, ICUS, MBL, or early low-grade lymphomas
- You must not have an active, symptom-causing blood cancer
- You can join even if you have a precursor condition trial or a prior cancer-like blood condition—this is about monitoring progression risk
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses advanced genetic testing to see if they can predict how monoclonal gammopathies (early blood conditions that may turn into cancer) will change over time. It may help doctors understand your risk better.
This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.
This study screens for MGUS, a precursor to certain blood cancers, in people who are Black or African American, or who have a close relative with a plasma cell disorder. If MGUS is found, you may be invited to continue in the study to monitor your health.
This study uses a special label (carbon 13) to track bone marrow cells in people with a pre-cancer condition called MGUS. It aims to learn how these cells work, which may help understand the condition better.
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
This study asks healthy adults to provide blood, bone marrow (if needed), skin, saliva, and stool samples. Scientists use these samples to compare patterns related to myeloid (bone-marrow) blood cancers, which may help future research and tests.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.